Protocol summary
-
Study aim
-
Objective: The aim of this study is to determine the effects of magnesium supplementation on gene expression related to insulin and lipid in patients of gestational diabetes.
-
Design
-
Design: Randomized double-blind placebo-controlled trial. Randomization will be done by the use of computer-generated random numbers. Patients will be assigned into two groups to receive magnesium supplements (n=20) or placebo (n=20).
-
Settings and conduct
-
Population and sample size: Among patients with gestational diabetes referred to gynecology Clinic affiliated to Arak University of Medical Sciences, 40 patients will be selected according to inclusion and exclusion criteria.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with gestational diabetes; aged 18 to 40 years. Exclusion criteria: Taking magnesium supplements within the past 3 months, needing to insulin therapy during the intervention, pre-eclampsia, eclampsia, hypo and hyperthyroidism, and smokers.
-
Intervention groups
-
Intervention: Patients will be assigned into two groups to receive magnesium (n=20) or placebo (n=20). Magnesium and placebos capsules are similar in shape and size. At the beginning and end of the intervention: 6 weeks.
-
Main outcome variables
-
Outcomes: Gene expression related to insulin (primary outcomes) and gene expression related to lipid (secondary outcome) will be quantified at study baseline and end-of-trial.
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT201704235623N111
Registration date:
2017-04-29, 1396/02/09
Registration timing:
retrospective
Last update:
2019-09-21, 1398/06/30
Update count:
1
-
Registration date
-
2017-04-29, 1396/02/09
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Expected recruitment start date
-
2017-03-07, 1395/12/17
-
Expected recruitment end date
-
2017-04-06, 1396/01/17
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Clinical trial of the effect of magnesium supplementation compared with the placebo on gene expression related to insulin and lipid in women with gestational diabetes
-
Public title
-
Effect of supplementation in treatment of women with gestational diabetes
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients with gestational diabetes
Aged 18 to 40 years
Exclusion criteria:
Taking magnesium supplements within the past 3 months
Needing to insulin therapy during the intervention
Pre-eclampsia
Eclampsia
Hypo and hyperthyroidism
Smokers
-
Age
-
From 18 years old to 40 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
40
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
At study baseline and after balanced blocked randomisation, subjects will be allocated into two groups to take either magnesium supplements (n=20) or placebo (n=20). Randomization will be done by the use of computer-generated random numbers.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Participants, investigators or the assessors of the outcomes are unaware of the study groups.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Randomization will be done by the use of computer-generated random numbers.
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2017-03-06, 1395/12/16
-
Ethics committee reference number
-
IR.ARAKMU.REC.1395.440
Health conditions studied
1
-
Description of health condition studied
-
Gestational diabetes
-
ICD-10 code
-
O24.9
-
ICD-10 code description
-
Diabetes mellitus in pregnancy, unspecified
Primary outcomes
1
-
Description
-
Expressed levels of PPAR-γ
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR
2
-
Description
-
Expressed levels of GLUT-1
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR
Secondary outcomes
1
-
Description
-
Expressed levels of LDLR gene
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR
2
-
Description
-
Expressed levels of Lp(a) gene
-
Timepoint
-
At the beginning of the study and after 6 weeks of intervention
-
Method of measurement
-
PCR
Intervention groups
1
-
Description
-
Intervention group: Magnesium supplements (21st Century, Arizona, USA), 250 mg, daily, for 6 weeks orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Placebo capsule, daily for 6 weeks orally.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available